An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules

An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules

The Wilms' tumor oncogene protein (WT1) is a highly validated tumor antigen for immunotherapy. WT1-targeted immunotherapy has been extensively explored in multiple human trials in various cancers. However, clinical investigations using WT1 epitopes have generally focused on two peptides, HLA-re...

Full description

Bibliographic Details
Main Authors: Tao Dao, Tatyana Korontsvit, Victoria Zakhaleva, Casey Jarvis, Patrizia Mondello, Claire Oh, David A. Scheinberg
Format: Article
Language:English
Published: Taylor & Francis Group 2017-02-01
Series:OncoImmunology
Subjects:
analog peptides
cancer vaccines
ctl response
immunotherapy
wt1
Online Access:http://dx.doi.org/10.1080/2162402X.2016.1252895

Internet

http://dx.doi.org/10.1080/2162402X.2016.1252895

Similar Items